Genedrive logo

GDR - Genedrive Share Price

136.3p 2.8  2.1%

Last Trade - 8:14am

Sector
Healthcare
Size
Small Cap
Market Cap £84.5m
Enterprise Value £78.8m
Revenue £1.06m
Position in Universe 1068th / 1810
Bullish
Bearish
Unlock GDR Revenue
Momentum
Relative Strength (%)
1m +33.9%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -55.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
4.52 5.06 2.62 1.94 2.36 1.06 3.10 9.85 -25.2%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 30 June 2020, GenedrivePLC revenues decreased 55% to £1.1M. Net loss increasedfrom £3.6M to £19.4M. Revenues reflect United Kingdomsegment decrease of 59% to £597K, United States segmentdecrease of 54% to £420K. Higher net loss reflectsDiagnostics Segment loss increase of 44% to £3.6M,Unallocated - Administrative segment loss increase of 36%to £2M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for GDR
Graphical History

Revenue

GDR Revenue Unlock GDR Revenue

Net Income

GDR Net Income Unlock GDR Revenue

Normalised EPS

GDR Normalised EPS Unlock GDR Revenue

PE Ratio Range

GDR PE Ratio Range Unlock GDR Revenue

Dividend Yield Range

GDR Dividend Yield Range Unlock GDR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
GDR EPS Forecasts Unlock GDR Revenue
Profile Summary

Genedrive Plc is a United Kingdom-based holding company engaged in molecular diagnostics business. The Company provides a molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. Its geographical segments include the United Kingdom, Europe, the United States of America and Asia. Genedrive is a small polymerase chain reaction (PCR) platform, which enables nucleic acid amplification and detection from various sample types, including plasma, sputum and buccal swabs. Genedrive system includes Genedrive hepatitis C virus (HCV) ID Kit for detection of Hepatitis C, and Genedrive IL28B ID Kit for the detection of Interleukin 28B genotyping status.

Directors
Last Annual June 30th, 2020
Last Interim June 30th, 2020
Incorporated February 15, 2007
Public Since April 4, 2007
No. of Shareholders: n/a
No. of Employees: 46
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 63,310,048
Free Float (0.0%)
Eligible for
ISAs
SIPPs
GDR Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for GDR
Upcoming Events for GDR
Frequently Asked Questions for Genedrive
What is the Genedrive share price?

As of 8:14am, shares in Genedrive are trading at 136.3p, giving the company a market capitalisation of £84.5m. This share price information is delayed by 15 minutes.

How has the Genedrive share price performed this year?

Shares in Genedrive are currently trading at 136.3p and the price has moved by 1.38k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Genedrive price has moved by 1.21k% over the past year.

What are the analyst and broker recommendations for Genedrive?

Of the analysts with advisory recommendations for Genedrive, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Genedrive is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Genedrive next release its financial results?

Genedrive is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Genedrive dividend yield?

Genedrive does not currently pay a dividend.

Does Genedrive pay a dividend?

Genedrive does not currently pay a dividend.

When does Genedrive next pay dividends?

Genedrive does not currently pay a dividend.

How do I buy Genedrive shares?

To buy shares in Genedrive you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Genedrive?

Shares in Genedrive are currently trading at 136.3p, giving the company a market capitalisation of £84.5m.

Where are Genedrive shares listed? Where are Genedrive shares listed?

Here are the trading details for Genedrive:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: GDR
What kind of share is Genedrive?

Based on an overall assessment of its quality, value and momentum, Genedrive is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Genedrive share price forecast 2021?

Shares in Genedrive are currently priced at 136.3p. At that level they are trading at 68.54% premium to the analyst consensus target price of 80.87.

Analysts covering Genedrive currently have a consensus Earnings Per Share (EPS) forecast of -0.093 for the next financial year.

How can I tell whether the Genedrive share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genedrive. Over the past six months, the relative strength of its shares against the market has been 31.9%. At the current price of 136.3p, shares in Genedrive are trading at 42.6% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Genedrive PE Ratio?

We were not able to find PE ratio data for Genedrive.

Who are the key directors of Genedrive?

Genedrive's management team is headed by:

Ian Gilham - NEC
David Budd - CEO
Matthew Fowler - CFO
Tom Lindsay - NED
Christopher Yates - NED
Who are the major shareholders of Genedrive?

Here are the top five shareholders of Genedrive based on the size of their shareholding:

Calculus Capital Limited Private Equity
Percentage owned: 5.62% (3.56m shares)
Global Health Investment Co., Ltd. Corporation
Percentage owned: 4.26% (2.70m shares)
River and Mercantile Asset Management LLP Investment Advisor/Hedge Fund
Percentage owned: 2.87% (1.82m shares)
Rylands (Hugh John Joseph) Individual Investor
Percentage owned: 2.66% (1.69m shares)
Spreadex, Ltd. Corporation
Percentage owned: 2.57% (1.63m shares)
Similar to GDR
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.